

# From Sequence Design to AOC Production: Medicilon's End-to-End RNAi Development Platform




Ao Huang, Lei Qian, Maosheng Du, Bin Yan, Zhengyu Luo, Qingcong Li, and Steven Zhang

<sup>1</sup> Shanghai Medicilon Inc., 585 Chuanda Road, Shanghai 201299, China, USA Corp., 20 Maguire Road, Suite 103, Lexington, MA 02421, USA.

Anchored by a sophisticated RNAi platform, our AOC capabilities are supported by advanced conjugation chemistry and analytical methods, and enabled by integrated expertise spanning sequence design, nucleotide synthesis, and in vivo evaluation, together providing a one-stop solution for oligonucleotide therapeutics.

**Medicilon Optimal Design (MOD)**

**Mono-Nucleotide Synthesis**



**Delivery & Carrier Synthesis**